Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that autologous Foxp3+ γδTregs, when tested in human scalp hair follicle models and mouse xenotransplants, can both prevent and treat alopecia areata by reducing immune privilege collapse and lymphocytic infiltration, suggesting their potential as a novel cell-based therapy for the disease.

In this pilot study, minoxidil-treated scalp skin grafts from hair loss patients on mice showed increased expression of key anti-aging biomarkers and hair regrowth, suggesting minoxidil as a potential anti-aging agent by boosting VEGF-A production in hair follicles.

This study suggests that vellus to terminal hair follicle reconversion can occur in male pattern androgenetic alopecia using an in vivo model with minoxidil and platelet-rich plasma treatment.

Minoxidil rejuvenates hair follicles and reduces aging signs in male pattern baldness.

This review explores animal models of alopecia areata, particularly focusing on the insights they've provided into the disease's immune mechanisms and potential treatment approaches, without reporting new experimental data.

This study found that ILC1-like cells can induce alopecia areata in healthy human hair follicles, suggesting that these cells might be a therapeutic target in AA management.

Kv1.3 blockers may help treat alopecia areata and promote hair regrowth.

This study observed that the osteopontin-derived peptide FOL-005 inhibited hair growth in human scalp skin models, contrary to its hair growth promotion in mice, supporting further clinical testing for excessive hair growth treatment.

This article outlines methods to study the skin and its molecular traits, focusing on interpretation and techniques applicable to mouse models, including diverse assays and approaches like electron microscopy and large-scale lipid analyses.

This study found that a newly developed peptide, FOL-005, significantly inhibited hair growth and counteracted minoxidil's effects in organ-cultured human male scalp skin and mouse models, without apparent toxicity.

This study developed an animal model that recreates alopecia areata by injecting healthy human skin grafts in immunocompromised mice with peripheral blood mononuclear cells enriched for NKG2D+ and CD56+ cells.

This study provides evidence that innate lymphoid cells-type 1 can induce alopecia areata in human hair follicles, challenging the view that it is solely a CD8+ T cell-driven autoimmune disease.

In this study, researchers successfully generated functional and long-lived melanocytes from human embryonic stem cells, demonstrating their biocompatibility and high engraftability in mice, which may aid in developing treatments for pigmentary skin disorders.

This study found that human γδTregs promoted hair regrowth and restored hair follicle immune privilege in a model of alopecia areata, suggesting potential for cell-based therapy in autoimmune diseases.

In this study, γδTregs showed potential as a cell-based therapy for alopecia areata by preventing hair loss and promoting hair regrowth in humanized AA models.

This study found that autologous γdTregs displayed significant protective effects on alopecia areata-affected human scalp hair follicles in both ex vivo and in vivo settings, suggesting potential for future cell-based therapy.

This study using a humanized mouse model of androgenetic alopecia suggests that platelet-rich plasma may promote hair regrowth and improve hair characteristics in vivo.

In this study, iNKT10 cells were found to play a significant role in preventing and treating alopecia areata in a humanized mouse model, suggesting these cells could have potential in managing related autoimmune disorders.

This study found that induced expression of mir-302 can reprogram human hair follicle cells into induced pluripotent stem cells through a novel epigenetic mechanism involving global demethylation.

This review summarizes recent advances in Treg cell biology, focusing on Foxp3's role in immune regulation and therapeutic reprogramming for immune dysregulatory disorders, but reports no new clinical results.

This review discusses the clinical manifestations and immune response to Rhodococcus equi infection in foals but reports no new clinical results.

This review discusses the development and application of cell-derived matrices in regenerative medicine and disease modeling, presenting various fabrication techniques and future perspectives, but reports no new results.

This review emphasizes the potential of repurposing topical L-thyroxine for skin ulcers and telogen effluvium and highlights the need for further exploration of its use in dermatology.

This review discusses the use of phosphodiesterase inhibitors for alopecia, finding promising preliminary results with topical caffeine for androgenetic alopecia and telogen effluvium, but limited success in alopecia areata.

This review discusses the role of immune cells in the pathogenesis of alopecia areata and highlights emerging immunomodulatory strategies and novel therapeutic targets aimed at offering more effective and durable treatments for this autoimmune hair loss disorder.

This study found that Rosebay extract significantly reduced dandruff and sebum production, suggesting it may be an effective anti-dandruff ingredient as a complement or alternative to antifungal treatments.

This study observed that uncommon finasteride side effects included melasma, dry skin, tinnitus, postural hypotension, and oral lesions, with some symptoms persisting after treatment cessation.

This study found that adverse effects of finasteride were more common among right-handed heterosexuals and left-handed homosexuals with androgenic alopecia.

This study found that among men unresponsive to finasteride for androgenic alopecia, 56.25% showed significant hair improvement after six months of dutasteride treatment with reasonable adverse effects.

This study reviews recent advancements in understanding caspases, highlighting their roles beyond apoptosis in cancer, inflammation, and neurological disorders, and discusses the potential and challenges of targeting caspases for therapeutic purposes.